|
PRX-07034
|
DB05993 |
|
|
Indirubin-3'-monoxime
|
DB02052 |
|
|
Fica
|
DB03384 |
|
|
4-Nitrophenyl (3S)-3-({N-[(benzyloxy)carbonyl]-L-phenylalanyl}amino)-5-phenyl-1-pentanesulfonate
|
DB02051 |
|
|
4-Methylimidazole
|
DB03385 |
|
|
S-oxy-L-cysteine
|
DB03382 |
|
|
Gabaculine
|
DB02054 |
|
|
5-Chloro-1h-Indole-2-Carboxylic Acid [1-(4-Fluorobenzyl)-2-(4-Hydroxypiperidin-1yl)-2-Oxoethyl]Amide
|
DB03383 |
|
|
Ribose-5-phosphate
|
DB02053 |
|
|
L-tyrosinamide
|
DB03380 |
|
|
Hexadecanal
|
DB03381 |
|
|
beta-Sitosterol
|
DB14038 |
[Active fraction of Solanum trilobatum; reduces side-effects of radiation-induced toxicity.] |
|
Aganirsen
|
DB15369 |
[Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG).] |
|
Erenumab
|
DB14039 |
[Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the CGRP receptor, which is believed to play a critical role in migraine [L2823].
In particular, erenumab-aooe is a human immunoglobulin G2 monoclonal antibody that has high affinity binding to the CGRP receptor [FDA Label]. The antibody is produced utlilizing recombinant DNA technology in Chinese hamster ovary cells [FDA Label]. It is composed of 2 heavy chains, each containing 456 amino acids, and 2 light chains of the lambda subclass, each containing 216 amino acids, with an approximate molecular weight of 150 kDa [FDA Label].] |
|
Darglitazone
|
DB14034 |
|
|
SOR-C13
|
DB15366 |
[SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).] |
|
Pegbelfermin
|
DB15365 |
[Pegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis).] |
|
Englitazone
|
DB14035 |
[Englitazone is a hypoglycemic agent.] |
|
Yttrium Y-90 clivatuzumab tetraxetan
|
DB15368 |
[Yttrium Y-90 clivatuzumab tetraxetan is under investigation in clinical trial NCT00603863 (Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer).] |
|
Madecassic acid
|
DB14037 |
|
